Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients : A Retrospective Analysis
Comprehensive genomic profiling (CGP) allows for the detection of driver alterations at high resolution, but the limited number of approved targeted therapies and their high costs have contributed to its limited clinical utilization. We retrospectively compared data of 946 women with ovarian cancer (11.4% were referred to CGP, and 88.6% served as control) to examine whether CGP provides a prognosis benefit. Patient baseline parameters were similar between the groups. Cox regression analysis adjusted for age, disease stage at diagnosis, and recurrence status showed statistically significantly longer median overall survival (mOS) in the CGP group versus the control (73.4 versus 54.5 months, p < 0.001). Fifty-four patients (52.9%) had actionable mutations with potential treatments; twenty-six (48.2%) were treated with matched targeted therapy, showing a trend for longer mOS than the eighty-six women in the CGP group who were not given a suggested treatment (105.5 versus 63.6 months, p = 0.066). None of the genomic alterations predicted metastasis location. CCNE1 amplification and KRAS mutations were associated with shorter mOS. Patients with tumor mutation burden ≥4 mutations/megabase had longer mOS. High loss of heterozygosity was associated with longer mOS (99.0 versus 48.2 months, p = 0.004). CGP testing may provide both prognostic and predictive insights for treatment of patients with ovarian cancer. Prospective studies of larger cohorts are warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2022), 1 vom: 29. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peleg Hasson, Shira [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comprehensive genomic profiling |
|---|
| Anmerkungen: |
Date Revised 08.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15010218 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351233040 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351233040 | ||
| 003 | DE-627 | ||
| 005 | 20231226050851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15010218 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351233040 | ||
| 035 | |a (NLM)36612212 | ||
| 035 | |a (PII)218 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peleg Hasson, Shira |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients |b A Retrospective Analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Comprehensive genomic profiling (CGP) allows for the detection of driver alterations at high resolution, but the limited number of approved targeted therapies and their high costs have contributed to its limited clinical utilization. We retrospectively compared data of 946 women with ovarian cancer (11.4% were referred to CGP, and 88.6% served as control) to examine whether CGP provides a prognosis benefit. Patient baseline parameters were similar between the groups. Cox regression analysis adjusted for age, disease stage at diagnosis, and recurrence status showed statistically significantly longer median overall survival (mOS) in the CGP group versus the control (73.4 versus 54.5 months, p < 0.001). Fifty-four patients (52.9%) had actionable mutations with potential treatments; twenty-six (48.2%) were treated with matched targeted therapy, showing a trend for longer mOS than the eighty-six women in the CGP group who were not given a suggested treatment (105.5 versus 63.6 months, p = 0.066). None of the genomic alterations predicted metastasis location. CCNE1 amplification and KRAS mutations were associated with shorter mOS. Patients with tumor mutation burden ≥4 mutations/megabase had longer mOS. High loss of heterozygosity was associated with longer mOS (99.0 versus 48.2 months, p = 0.004). CGP testing may provide both prognostic and predictive insights for treatment of patients with ovarian cancer. Prospective studies of larger cohorts are warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a comprehensive genomic profiling | |
| 650 | 4 | |a genomic alterations | |
| 650 | 4 | |a matched therapy | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a overall survival | |
| 700 | 1 | |a Hershkovitz, Dov |e verfasserin |4 aut | |
| 700 | 1 | |a Adar, Lyri |e verfasserin |4 aut | |
| 700 | 1 | |a Brezis, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Shachar, Eliya |e verfasserin |4 aut | |
| 700 | 1 | |a Aks, Rona |e verfasserin |4 aut | |
| 700 | 1 | |a Galmor, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Raviv, Yuval |e verfasserin |4 aut | |
| 700 | 1 | |a Ben Neriah, Shira |e verfasserin |4 aut | |
| 700 | 1 | |a Merimsky, Ofer |e verfasserin |4 aut | |
| 700 | 1 | |a Sabo, Edmond |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Ido |e verfasserin |4 aut | |
| 700 | 1 | |a Safra, Tamar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2022), 1 vom: 29. Dez. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:1 |g day:29 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15010218 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 1 |b 29 |c 12 | ||